Indegene

Last updated

Indegene
FormerlyIndegene Lifesystems [1]
Company type Public
Industry
Founded1998;26 years ago (1998)
FoundersRajesh Nair
Manish Gupta
Sanjay Parikh
Anand Kiran
Gaurav Kapoor
Headquarters
Bangalore
,
India
Area served
Worldwide
Key people
Manish Gupta (CEO) [2]
RevenueIncrease2.svg₹2,306 crore (US$290 million) (FY23) [3]
Increase2.svg₹266 crore (US$33 million) (FY23) [3]
Owners
Number of employees
4,100 (2021) [4]
Website www.indegene.com

Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises. [5] [6] [7] Based in Bangalore, the company specializes in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics. [4] [8]

Contents

History

Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran. [9] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States. [10] In 2008, Medsn officially became known as Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States. [7] [11]

In 2009, Indegene signed a master service agreement with six pharmaceutical companies. [6] [12] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million. [13] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014. [14]

In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million. [15]

In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene. [16] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million. [17]

Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$230 million). It listed on the BSE and the NSE. [18]

Operations

Indegene has offices in India, the United States, the European Union, and Asia-Pacific. [19] [11]

In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry. [20]

See also

Related Research Articles

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Cinven Limited is a global private equity firm founded in 1977, with offices in nine international locations in Guernsey, London, New York, Paris, Frankfurt, Milan, Luxembourg, Madrid, and Hong Kong that acquires Europe and United States based corporations, and emerging market firms that fit with their core businesses, and necessitate a minimum equity investment of €100 million or more. As of 2023, it has €39 billion in assets under management.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Otsuka Pharmaceutical</span> Japanese pharmaceutical company

Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

IMS Health was an American company that provided information, services and technology for the healthcare industry. IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. The company went public on April 4, 2014, and began trading on the NYSE under the symbol IMS. IMS Health was headquartered in Danbury, Connecticut.

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook and operates the Parexel-Academy.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Nimmagadda Prasad</span> Indian businessman

Nimmagadda Prasad is an Indian industrialist from Andhra Pradesh, India. He is known for his ventures in the Pharmaceutical and Television industries, and is involved in philanthropic activities through Nimmagadda Foundation.

<span class="mw-page-title-main">Fortis Healthcare</span> Indian multinational chain of private hospitals

Fortis Healthcare Limited (FHL) is an Indian for-profit private hospital network headquartered in Gurgaon, India. Fortis started its health care operations in Mohali, Punjab, where the first Fortis hospital was started. Later on, the hospital chain purchased the healthcare branch of Escorts group and increased its strength in various parts of the country. The Escorts Heart and Research Center, Okhla, Delhi became a major operating unit of the chain. Dr. Tehran, the current MD of Medanta and several others have started their careers at this institute.

Real Chemistry, formerly known as W2O Group, is a global health innovation company that utilizes artificial intelligence (AI) for its healthcare services. Founded by Jim Weiss in 2001, Real Chemistry is an American company with global offices in Europe and Canada.

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services. It was listed on the London Stock Exchange until it was acquired by American private equity company Clayton, Dubilier & Rice in August 2021.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Rubicon Research is an IP led, specialty pharmaceutical company located in Mumbai, India. Its formulation development is across multiple dosage forms, oral solids, oral liquids, nasal, ophthalmic, topical, injectable, fixed dose combinations, and drug device combinations. In 2019 the company received USD 100 million in growth capital investment from General Atlantic, a growth equity firm.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. It's market presence is more than 100+ countries.

<span class="mw-page-title-main">Mankind Pharma</span> Indian pharmaceutical and healthcare products company

Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

Quantum Pharma Plc is a manufacturer and supplier of unlicensed medicines and Special Obtain products based in Burnopfield, County Durham. As of 2014, Andrew Scaife was the company's chief executive officer (CEO), who had joined the company's management team in 2009.

Omnicell, Inc. is an American multinational healthcare technology company headquartered in Fort Worth, Texas. It manufactures automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. Its products are sold under the brand names Omnicell and EnlivenHealth.

PharmEasy is an Indian e-pharmacy company that sells medicines, diagnostics and telehealth online.

References

  1. ↑ Mendonca, Jochelle (28 November 2015). "Healthcare IT firm Indegene targets $250 million in revenue by 2020, looking at Nasdaq IPO". The Economic Times. Retrieved 28 April 2024.
  2. ↑ "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
  3. 1 2 3 "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
  4. 1 2 Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei . Retrieved 2 October 2015.
  5. ↑ Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times . Retrieved 2 October 2015.
  6. 1 2 Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint . Retrieved 2 October 2015.
  7. 1 2 Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard . Retrieved 2 October 2015.
  8. ↑ "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
  9. ↑ Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times . Retrieved 2 October 2015.
  10. ↑ D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times . Retrieved 2 October 2015.
  11. 1 2 "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
  12. ↑ "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Retrieved 2 October 2015.
  13. ↑ Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India . Retrieved 2 October 2015.
  14. ↑ Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
  15. ↑ Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
  16. ↑ Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint . Retrieved 20 August 2021.
  17. ↑ Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
  18. ↑ Narayanan, KS Badri (6 May 2024). "Indegene IPO opens today in ₹430-452 price band". BusinessLine. Retrieved 6 May 2024.
  19. ↑ Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Retrieved 2 October 2015.
  20. ↑ "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times . 16 July 2012. Retrieved 2 October 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.